Frontotemporal Dementia Clinical Trial
— ReRescuePGROfficial title:
Rehabilitative Trial for the Recovery of Neurophysiological Parameters in Progranulin Mutation Carriers Through the Use of Transcranial Direct Current Stimulation (tDCS)
NCT number | NCT02999282 |
Other study ID # | NP2441 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 31, 2016 |
Est. completion date | June 30, 2019 |
Verified date | March 2020 |
Source | Azienda Ospedaliera Spedali Civili di Brescia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this randomized, double-blind, sham-controlled study, the investigators will evaluate the effects of frontal and prefrontal anodal transcranial direct current stimulation (tDCS) on neurophysiological parameters of cortical connectivity, assessed by transcranial magnetic stimulation (TMS), in asymptomatic subjects bearing a pathogenic GRN mutation and in symptomatic patients with frontotemporal dementia.
Status | Completed |
Enrollment | 70 |
Est. completion date | June 30, 2019 |
Est. primary completion date | June 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: presymptomatic carriers, symptomatic genetic FTD patients, symptomatic
sporadic FTD patients. - Presymptomatic carriers: defined as participants who are known carriers of a pathogenic mutation in the GRN gene, who do not fulfill current criteria for the behavioral variant FTD (bvFTD) (Rascovsky et al. 2011) or for the Primary Progressive Aphasias (PPA) (Gorno-Tempini et al. 2011). All subjects will be genotyped for known pathogenic mutations for FTD (GRN, C9orf72, MAPT, TDP-43) before participation. - Symptomatic genetic FTD: defined as patients who are known carriers of pathogenic mutation in the GRN gene, fulfilling current clinical criteria for behavioral variant FTD (bvFTD) (Rascovsky et al. 2011) or the agrammatic variant of Primary Progressive Aphasia (avPPA) (Gorno-Tempini et al. 2011). - Symptomatic sporadic FTD: defined as patients fulfilling current clinical criteria for behavioral variant FTD (bvFTD) (Rascovsky et al. 2011) or the agrammatic variant of Primary Progressive Aphasia (avPPA) (Gorno-Tempini et al. 2011), with a negative screening for pathogenic mutations in known FTD genes (GRN, C9orf72, MAPT, TDP-43). CSF analysis or amyloid PET imaging will be carried out to exclude focal variants of AD. Exclusion Criteria: - Cerebrovascular disorders, previous stroke, hydrocephalus, and intra-cranial mass documented by MRI. - History of traumatic brain injury or other neurological diseases. - Serious medical illness other than FTD - History of seizures - Pregnancy - Metal implants in the head (except dental fillings) - Electronic implants (i.e. pace-maker, implanted medical pump) - Age <18 years |
Country | Name | City | State |
---|---|---|---|
Italy | Azienda Ospedaliera Spedali Civili di Brescia | Brescia |
Lead Sponsor | Collaborator |
---|---|
Azienda Ospedaliera Spedali Civili di Brescia |
Italy,
Benussi A, Cosseddu M, Filareto I, Dell'Era V, Archetti S, Sofia Cotelli M, Micheli A, Padovani A, Borroni B. Impaired long-term potentiation-like cortical plasticity in presymptomatic genetic frontotemporal dementia. Ann Neurol. 2016 Sep;80(3):472-6. doi: 10.1002/ana.24731. Epub 2016 Aug 10. — View Citation
Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP, Kronberg G, Truong D, Boggio P, Brunoni AR, Charvet L, Fregni F, Fritsch B, Gillick B, Hamilton RH, Hampstead BM, Jankord R, Kirton A, Knotkova H, Liebetanz D, Liu A, Loo C, Nitsche MA, Reis J, Richardson JD, Rotenberg A, Turkeltaub PE, Woods AJ. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-661. doi: 10.1016/j.brs.2016.06.004. Epub 2016 Jun 15. Review. — View Citation
Rossini PM, Burke D, Chen R, Cohen LG, Daskalakis Z, Di Iorio R, Di Lazzaro V, Ferreri F, Fitzgerald PB, George MS, Hallett M, Lefaucheur JP, Langguth B, Matsumoto H, Miniussi C, Nitsche MA, Pascual-Leone A, Paulus W, Rossi S, Rothwell JC, Siebner HR, Ugawa Y, Walsh V, Ziemann U. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee. Clin Neurophysiol. 2015 Jun;126(6):1071-1107. doi: 10.1016/j.clinph.2015.02.001. Epub 2015 Feb 10. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in SICI measurements from Baseline | By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of frontal and prefrontal anodal transcranial magnetic stimulation on short interval intracortical inhibition (SICI) | Baseline - 2 weeks | |
Primary | Change in ICF measurements from Baseline | By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of frontal and prefrontal anodal transcranial magnetic stimulation on intracortical facilitation (ICF). | Baseline - 2 weeks | |
Secondary | Change in SICI measurements from Baseline | By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of frontal and prefrontal anodal transcranial magnetic stimulation on short interval intracortical inhibition (SICI) | Baseline - 1 month - 3 months - 6 months | |
Secondary | Change in ICF measurements from Baseline | By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of frontal and prefrontal anodal transcranial magnetic stimulation on intracortical facilitation (ICF). | Baseline - 1 month - 3 months - 6 months | |
Secondary | Change in LICI measurements from Baseline | By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of frontal and prefrontal anodal transcranial magnetic stimulation on long interval intracortical inhibition (LICI). | Baseline - 1 month - 3 months - 6 months | |
Secondary | Change in SICF measurements from Baseline | By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of frontal and prefrontal anodal transcranial magnetic stimulation on short interval intracortical facilitation (SICF). | Baseline - 1 month - 3 months - 6 months | |
Secondary | Change in MMSE scores from Baseline | The Mini Mental State Examination (MMMSE) is a 30-point questionnaire that is used to measure cognitive impairment. | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in phonemic fluencies scores from Baseline | Produce as many words as possible beginning with a specified letter in 60 seconds | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in semantic fluencies scores from Baseline | Produce as many words as possible from a category in 60 seconds | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in digit span forward scores from Baseline | Participants hear a sequence of numerical digits and are tasked to recall the sequence correctly, with increasingly longer sequences being tested in each trial. The participant's span is the longest number of sequential digits that can accurately be remembered. | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in digit span backward scores from Baseline | Participants hear a sequence of numerical digits and are tasked to recall the sequence correctly in reverse order, with increasingly longer sequences being tested in each trial. The participant's span is the longest number of sequential digits that can accurately be remembered. | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in camel and cactus test scores from Baseline | Evaluates associative semantic memory with 64 items presented for naming and word-picture matching. | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in TMTA scores from Baseline | The task requires a subject to connect a sequence of 25 consecutive targets on a sheet of paper to examine cognitive processing speed. | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in TMTB scores from Baseline | The task requires a subject to connect a sequence of 25 consecutive targets on a sheet of paper, alternating between numbers and letters, to examine executive functioning. | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in Stroop test scores from Baseline | Measure a person's selective attention capacity and skills, as well as their processing speed ability. | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in Symbol Digit test scores from Baseline | It consists of digit-symbol pairs followed by a list of digits. Under each digit the subject should write down the corresponding symbol as fast as possible. The number of correct symbols within the allowed time is measured. | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in Block Design test scores from Baseline | To evaluated spatial visualization ability and motor skills. The test-taker uses hand movements to rearrange blocks that have various color patterns on different sides to match a pattern. The items in a block design test are scored both by accuracy in matching the pattern and by speed in completing each item. | Baseline - 2 weeks - 3 months - 6 months | |
Secondary | Change in The modified EkmanFaces Test from Baseline | Each face is presented on a sheet with six labels of basic emotions below the photograph. The patient was required to respond verbally, deciding the label that best described the facial expression shown. | Baseline - 2 weeks - 3 months - 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT03272230 -
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
|
N/A | |
Active, not recruiting |
NCT03987295 -
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
|
Phase 2 | |
Withdrawn |
NCT05497817 -
A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia
|
N/A | |
Recruiting |
NCT04918251 -
EEG and TMS-based Biomarkers of ALS, MS and FTD
|
||
Completed |
NCT01002300 -
Oxytocin and Social Cognition in Frontotemporal Dementia
|
N/A | |
Completed |
NCT01890343 -
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
|
Phase 2 | |
Completed |
NCT00376051 -
Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia
|
Phase 4 | |
Terminated |
NCT00159198 -
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
Phase 1 | |
Active, not recruiting |
NCT04516499 -
Neurofilament Surveillance Project (NSP)
|
||
Recruiting |
NCT04747431 -
A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)
|
Phase 1/Phase 2 | |
Completed |
NCT03636204 -
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
|
Phase 1 | |
Completed |
NCT01937013 -
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia
|
Phase 2 | |
Active, not recruiting |
NCT05075187 -
Epidemiological Study in FRONtoTemporal Dementia
|
||
Not yet recruiting |
NCT05004558 -
Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias
|
N/A | |
Completed |
NCT00594737 -
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
|
Phase 3 | |
Recruiting |
NCT03225144 -
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
||
Active, not recruiting |
NCT04993755 -
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
|
Phase 2 | |
Recruiting |
NCT04114994 -
Longitudinal Cognitive Assessment by BoCA
|
||
Recruiting |
NCT04408625 -
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
|
Phase 1/Phase 2 |